NEW YORK, March 8, 2018 /PRNewswire/ —

According to Hexa Research, the U.S. medical cannabis market was esteemed to be valued at USD 5.44 billion in 2016 and is anticipated to be valued at USD 19.48 billion by 2024. The projected growth is a direct effect of the growing acceptance of cannabis products around the country. A wider range of consumers are aware of the medical advantages associated with cannabis, particularly for patients dealing with cancer, chronic pain and diabetes. Chronic pain accounted for 46 percent of the U.S. cannabis medical market share in 2016. According to the research, the solid cannabis edibles segment in 2016, within the U.S. market generated $2.47 billion in revenue and is expected to continue to dominate the cannabis industry to 2024. WeedMD Inc (OTC: WDDMF), Kush Bottles, Inc. (OTC: KSHB), Cannabis Sativa, Inc. (OTC: CBDS), Phivida Holdings Inc. (OTC: PHVAF), AXIM Biotechnologies, Inc. (OTC: AXIM)

California’s new recreational cannabis laws went into effect on January 1st, 2018. A report by Fortune indicates that, “In order to collect $1 billion a year in taxes, the state will need to reach a projected $7 billion in annual legal recreational cannabis sales. At that rate, California would easily be the country’s largest legal marijuana market, as the entire legal cannabis industry in the U.S. is expected to pull in roughly $10 billion in total sales for 2017. That number would almost certainly get a boost in the coming years, as legal markets grow in California and other states, such as Nevada and Massachusetts.”

WeedMD Inc (OTC: WDDMF) is also listed on the TSX Venture Exchange under the ticker symbol ‘WMD’. Just announced breaking news this morning that, “to announce the signing of a letter of intent (“LOI”) to form a joint venture focused on cannabis-infused beverages. The new joint venture company, Cannabis Beverages Inc. (“CanBev”), plans to

Read More Here...